Related references
Note: Only part of the references are listed.The Mitochondrial Pyruvate Carrier: Has It Been Unearthed at Last?
Andrew P. Halestrap
CELL METABOLISM (2012)
Insulin Resistance and Metabolic Derangements in Obese Mice Are Ameliorated by a Novel Peroxisome Proliferator-activated Receptor γ-sparing Thiazolidinedione
Zhouji Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Identification and Functional Expression of the Mitochondrial Pyruvate Carrier
Sebastien Herzig et al.
SCIENCE (2012)
A Mitochondrial Pyruvate Carrier Required for Pyruvate Uptake in Yeast, Drosophila, and Humans
Daniel K. Bricker et al.
SCIENCE (2012)
HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events
Robert S. Rosenson et al.
CLINICAL CHEMISTRY (2011)
Selective Insulin Sensitizers
Ja Young Kim-Muller et al.
SCIENCE (2011)
Projecting the Future Diabetes Population Size and Related Costs for the US
Elbert S. Huang et al.
DIABETES CARE (2009)
Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy
Wolfgang C. Winkelmayer et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia
Mark A. Deeg et al.
DIABETES CARE (2007)
Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose
MA Abdul-Ghani et al.
DIABETES CARE (2006)
Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030
S Wild et al.
DIABETES CARE (2004)
Clinical pharmacokinetics of pioglitazone
DA Eckland et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2000)
Share Paper
